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We show that intraepithelial cell neutralization of HIV by IgA antibodies to internal viral proteins can occur during antibody transcytosis from
the basolateral to the apical surface. Polarized epithelial cells expressing the polymeric immunoglobulin receptor (pIgR) were transfected with
HIV proviral DNA, and IgA was added to the basolateral side. Transcytosing IgA antibodies against Gag and RT significantly inhibited HIV
replication as assessed by infection of HeLa-CD4-LTR/β-Gal cells and direct p24 assay. Consistent with intracellular neutralization, colocalization
of the internal virus proteins and their IgA antibodies was demonstrated by confocal microscopy. Thus, at least in the context of infections of
polarized epithelia, antibody-mediated neutralization may not be restricted to viral surface antigens.
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HIV occur through contact with a mucosal surface (Smith and
Wahl, 2005), which acts as a gateway to the body. Suggested
mechanisms of entry include viral transcytosis across epithelial
cells or their tight junctions, infection of lymphoid cells through
breaches in the epithelial lining, and infection of epithelial cells
(Amerongen et al., 1991; Bomsel, 1997; Fantini et al., 1991,
1992; Han et al., 2000; Hu et al., 2000; Lagaye et al., 2001;
Moore et al., 2002, 2003; Qureshi et al., 1995; Spira et al., 1996).
The protective functions of the principal class of mucosal
antibody IgA depend on pIgR-mediated endocytosis at the
basolateral surface of epithelial cells and subsequent transcy-
tosis. This process makes it possible for IgA to (a) block viral
adherence or (b) bind virus in the lamina propria or in an
epithelial cell and transport it into the lumen (Bomsel et al.,
1998; Mazanec et al., 1992, 1993, 1995; Yan et al., 2002).
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doi:10.1016/j.virol.2006.08.006in the particular case of viruses as “virus excretion” (Kaetzel et al.,
1991; Robinson et al., 2001; Yan et al., 2002). On the other hand,
we have used the term “intracellular neutralization” to describe
antibody that inhibits virus production through an intracellular
action (Mazanec et al., 1992, 1993, 1995; Yan et al., 2002). Such
intraepithelial cell neutralization has been shown for IgA
antibodies against Sendai virus, measles, influenza, rotavirus,
andHIV (Burns et al., 1996; Feng et al., 2002; Fujioka et al., 1998;
Huang et al., 2005; Mazanec et al., 1992, 1995; Schwartz-Cornil
et al., 2002; Yan et al., 2002).
Resistance to HIV has been correlated with the presence of
specific mucosal IgA in uninfected sex workers and sexual
partners of infected individuals in some but not all studies
(Beyrer et al., 1999; Buchacz et al., 2001; Devito et al., 2000,
2002; Dorrell et al., 2000; Kaul et al., 1999, 2001; Mazzoli et al.,
1997, 1999; Skurnick et al., 2002), and anti-HIV IgA able to
neutralize T-cell line-adapted and primary HIV isolates has been
collected from both infected humans, even though anti-HIV IgA
responses tend not to be prominent (Burnett et al., 1994; Devito
et al., 2000; Kozlowski et al., 1995; Mestecky et al., 2004; Moja
et al., 2000; Wu et al., 2003) and mucosally immunized mice
(Akagi et al., 2003; Bukawa et al., 1995; VanCott et al., 1998).
Earlier we demonstrated that IgA antibodies against HIV
Table 1




Apical supernatant Cell lysate
Blue cell # % Virus
reduction b




RT IgA 84±23 38 c 1143±200 36 c
RT IgG 133±20 3 1851±197 0
Gag IgA 81±18 40 c 1176±128 35 c
Gag IgG 129±17 5 1777±164 1
Irrelevant IgA 131±27 4 1871±357 0
pIgR−cells
Control 152±12 1943±134
RT IgA 155±33 0 1872±127 4
Gag IgA 159±32 0 1933±137 1
a Polarized monolayers of pIgR+ or pIgR− Vero C1008 cells were transfected
with HIV proviral DNA for 4 h and then exposed to MAbs basolaterally for 18 h.
HIV levels in apical supernatants and cell lysates 30 h post transfection were
determined by infecting target HeLa cells (“blue cell” assay). Data are means
from eight data points±SEM pooled from four experiments.
b Compared to the no antibody control.
c Result significantly different (p<0.005) from the no antibody control
according to a two-tailed t test.
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(Huang et al., 2005). The neutralization is thought to result
from the fusion of transcytotic vesicles containing IgA antibody
with vesicles containing envelope protein that have budded off
the secretory pathway that is followed by proteins synthesized
in the rough endoplasmic reticulum and destined for cell surface
expression or export. In contrast to envelope proteins and the
secretory pathway, the subcellular trafficking of internal viral
proteins that are synthesized on free cytoplasmic ribosomes is
less well understood. Here we show that the less variant internal
HIV proteins Gag and RT can also be targets for antibody-
mediated intracellular neutralization. The results have implica-
tions for the design of mucosal vaccines.
Monoclonal antibody
Murine IgA monoclonal antibodies (MAb) against RT and the
structural protein p24 (Gag) were employed. The anti-Gag
hybridoma 183-H12-5C, which produces IgG1 (Chesebro et al.,
1992), was obtained from the NIH AIDS Research and Reagent
Program, and an IgA MAb switch variant was selected after
repeated cycles of limiting dilution and spontaneous isotype
switching (Boot et al., 1988). RT IgG and IgA hybridomas were
produced by immunizing mice with RT protein (kindly provided
by Stuart Le Grice, NIH). Production, purification, and
characterization of MAbs were performed as described (Yan et
al., 2002). IgA anti-gp120 was described in Huang et al. (2005).
The percent of oligomeric IgA, the form capable of binding to the
pIgR, was 84% and 68% for the RT and Gag IgAs respectively.
Transport of RT and Gag IgA
The ability of the MAbs to transcytose a polarized epithelial
membrane was tested with a monkey kidney cell line, Vero
C1008, stably transfected to express human pIgR (Huang et al.,
1999; Yan et al., 2002). Membrane polarization was tested by
monitoring electrical resistance between apical and basal
chambers. Transcytosis was assessed after adding 100 μg/ml
MAb to the basolateral chamber. Apical supernatants were
collected and analyzed by ELISA for Ig content. The amount of
anti-RT IgA transported at 4, 8, and 12 h was 149±19, 433±25,
and 557±37 ng, and for anti-Gag IgAwas 73±13, 145±21, and
237±15 ng. In contrast, the maximum amount of IgG, which
does not bind to pIgR, that reached the apical chamber at 12 h
was 26±2 ng.
Intracellular HIV neutralization
The ability of the MAbs to neutralize HIV inside polarized
epithelial cells was assayed as in Huang et al. (2005). Briefly,
polarized pIgR+ Vero cells were transfected with 2 μg of
proviral HIV DNA (pKS242) with a 4 h incubation before the
cells were washed and fresh medium added apically and either
medium or MAb added to the basolateral chamber for 18 h.
Then, cells were washed and fresh media added. After a 12 h
incubation, the apical and basolateral media were collected.
Monolayers were washed to remove extracellular virus, andcells were collected via scraping, freeze-thawed, and centri-
fuged to create cell lysate. HeLa (CD4-LTR/β-Gal) cells
expressing human CD4 and the HIV long terminal repeat
fused to a LacZ reporter gene (Kimpton and Emerman, 1992)
were infected with apical supernatant, basal medium, or cell
lysate, and the blue infected cells were counted 48 h after
infection (Huang et al., 2005).
Virus titers measured by the above blue cell assay were
decreased 38% and 40% (p<0.005) in the apical supernatants
by RT and Gag IgA and by 36% and 35% (p<0.005) in the cell
lysates compared to controls without antibody (Table 1). Virus
titers in the basal samples were too low to quantify (data not
shown). The IgAs capable of mediating this neutralization were
internalized by the pIgR since neither pIgR− cells with the same
IgAs nor pIgR+ cells with anti-RT or anti-Gag IgG showed
neutralization. Irrelevant IgA MAb (anti-measles virus hemag-
glutinin) did not neutralize, indicating that the intraepithelial
neutralization was immunologically specific (Table 1).
Concentration dependence of neutralization
Intracellular neutralization as a function of IgA antibody
concentration is shown in Table 2. For both anti-RT and anti-
Gag IgA, the reduction in virus titers decreased with lower
antibody concentrations. This was true for both apical super-
natants and cell lysates. A higher antibody concentration,
300 μg/ml, reduced virus production similarly to the 150 μg/ml
concentration (data not shown).
Confirmation that neutralization is intraepithelial
To verify that the neutralization observed was an intracel-
lular event, two conditioned media (C.M.) were prepared
Table 3

















Control 7.0±0.9 7.7±0.9 29.9±4.0
Anti-RT 6.2±1.4 11 c 6.3±0.5 18 c 26.7±4.2 11 c
Anti-Gag 6.3±1.4 10 c 6.2±1.7 19 c 26.7±2.3 11 c
a Experiments as in Table 1 except that p24 concentrations were measured.
MAbs were added for 18 h to the basolateral surface of polarized monolayers of
pIgR+ Vero C1008 cells that had been transfected with HIV proviral DNA for
4 h. HIV levels in apical supernatants, basolateral media, and cell lysates 30 h
post transfection were determined by p24 ELISA. Data are means from 11 data
points±SEM pooled from seven experiments.
b Compared to the no antibody control.
c Mean virus titer significantly less than control (p<0.02).
Table 2
IgA antibody concentration dependence of intracellular virus neutralization and
comparison to conditioned media a
IgA MAb (μg/ml) Apical supernatant Cell lysate
Blue cell # % Virus
reduction b
Blue cell # %Virus
reduction b
Control 156±26 1781±123
Anti-RT (150) 96±21 39 c 1075±125 40 c
Anti-RT (50) 115±14 26 c 1336±252 25 c
Anti-RT (20) 126±34 19 c 1674±133 6 c
Control 145±21 1814±76
Anti-Gag (150) 100±16 31 c 1330±158 27 c
Anti-Gag (50) 114±16 21 c 1489±122 18 c
Anti-Gag (20) 140±23 4 1808±202 1
Control 137±15 1776±43
Anti-RT (150) 82±14 40 1086±99 39 c
Anti-Gag (150) 80±20 42 c 1032±138 42 c
C.M.1—Anti-RT d 125±33 9 1707±114 4
C.M.1—Anti-Gag d 125±20 9 1774±124 2
C.M.2—Anti-RTe 1717±159 3
C.M.2—Anti-Gag e 1774±124 0
a Experiments as in Table 1 except that only pIgR+ epithelial cells were used.
In some cases conditioned medium (C.M.) was added to the apical chamber or
cell lysate without MAb having been added to the basolateral surface. Data are
means from eight data points±SEM pooled from four experiments.
b Compared to no antibody control.
c Result significantly different (p≤0.03) from the no antibody control.
d C.M.1—apical supernatant with transcytosed IgA (see text).
e C.M.2—IgA-transcytosing cell lysate (see text).
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transcytosed IgA in the apical compartment, C.M.1 was made
from apical supernatant of uninfected monolayers exposed
basolaterally to MAb. C.M.1 was then added apically to
infected monolayers not exposed to antibody basolaterally for
the final 12 h of incubation before collection as usual. The
results in Table 2 show that the apical supernatant viral titers
for C.M.1 of anti-RT and anti-Gag IgAs both had a 9%
(p>0.14) decrease compared to the significant decrease of
40–42% (p<0.005) when anti-RT and anti-Gag IgAs were
added basolaterally. Note that these MAbs against internal HIV
proteins lack conventional neutralizing activity, even at 50 μg/ml
(data not shown). C.M.1 also did not decrease viral titers in cell
lysates (4% versus 39% for transcytosing anti-RT (p<0.005) and
2% versus 42% for transcytosing anti-Gag (p<0.005)). The
finding that transcytosing IgA antibodies reduced virus titers in
apical supernatants and cell lysates significantly more than
previously transcytosed IgA antibodies in C.M.1 supports intra-
epithelial neutralization.
The other conditioned medium, C.M.2, was used to show
that neutralization did not result from the freeze–thaw cycle
releasing HIV and free antibody that subsequently complexed.
C.M.2 was generated from uninfected monolayers exposed
basolaterally to antibody, whose cells were then collected and
lysed. C.M.2 was used as the collection medium for infected
cell monolayers that were not exposed to MAb basolaterally.
C.M.2 containing anti-RT and anti-Gag yielded virus reductions
of 3% and 0% (Table 2) versus 39% and 42% for the
transcytosing antibodies in the standard assay. These results
further support the interpretation that the virus neutralizationobserved was due to IgA antibody binding viral antigen while
the antibody was traversing the cell.
Our data do not directly address the intracellular site where
transcytosing IgA antibody meets Gag and RT, both of which
are synthesized on cytoplasmic ribosomes. Nevertheless,
because both IgA and Gag utilize endosomes and multivesicular
bodies in their cellular trafficking (Apodaca et al., 1994; Gibson
et al., 1998; Nydegger et al., 2003; Ono and Freed, 2004;
Spearman, 2006; von Schwedler et al., 2003), it seems
reasonable to suggest a confluence of such vesicles as a likely
point of intersection.
Effect on p24 synthesis
To assess more directly the effect of transcytosing IgA
antibody on virus synthesis, p24 was measured by ELISA in
apical supernatant, basal medium, and cell lysate (Huang et al.,
2005). Concentrations of p24 in apical and basal media and cell
lysates were reduced by 11%, 18%, and 11% respectively by
anti-RT IgA compared to the no antibody control (all
p's≤0.01) (Table 3). For anti-Gag IgA, the reductions were
10%, 19%, and 11% (all p's<0.02). That p24 was decreased in
all three compartments by both anti-Gag and anti-RT IgA
antibody confirms that the reduced yield of virus observed was
not a result of intracellular virus being diverted to the apical
compartment.
Intracellular colocalization of viral antigen and antibody
Two-color immunofluorescence confocal microscopy was
used to visualize the interaction of transcytosing IgA antibody
with viral protein inside transfected epithelial cells (Fig. 1).
Monolayers were treated as above, but after 18–24 h exposure
to antibody basolaterally the monolayers were washed to
remove free antibody, fixed, permeabilized, and stained (Huang
et al., 2005). HIV proteins gp120, Gag, and RTwere stained red
with rhodamine, and IgA antibodies were stained green with
fluorescein (Huang et al., 2005). The gp120 protein was used
for comparison since it was previously demonstrated to
colocalize with transcytosing IgA anti-gp120 (Huang et al.,
2005). Merged images of IgA antibody and Gag or RT protein
Fig. 1. Intracellular colocalization of IgA antibodies and HIV proteins. When transfected, 5–10% of the cells produce virus and the Gag and RT IgAs neutralize 30–
40% of that virus. Apical (A), middle (M), and basal (B) horizontal sections through transfected cell monolayers were imaged. Each has a red (rhodamine) channel for
virus protein, a green (fluorescein) channel for IgA antibody, and merged red and green channels. Colocalization of red and green signals creates a yellow-orange color.
IgA antibodies and their HIV antigen showed colocalization in A, M, and B sections whereas irrelevant IgA showed little to no colocalization (scale bar=20 μm).
168 A. Wright et al. / Virology 356 (2006) 165–170show colocalization in all three cell planes, apical, middle, and
basal. Irrelevant IgA did not show colocalization with the HIV
proteins (RT protein shown).
Even though direct evidence for infection of mucosal
epithelial cells under natural conditions in humans is lacking,
because transmission of HIV usually occurs across mucosal
surfaces, the observations that IgA antibodies against both
envelope protein (Huang et al., 2005) and internal proteins (the
present study) can inhibit viral replication inside epithelial cells
may be relevant to vaccine strategies for HIV, as well as otherviruses. In our in vitro system, anti-Gag and anti-RT IgA
antibodies were less effective than anti-gp120 antibodies.
However, there have been difficulties in developing effective
vaccines with envelope protein antigens due to shielding by
glycosylation and high mutability. Therefore, the ability of
mucosal IgA antibodies to target the non-glycosylated and
relatively invariant internal antigens of HIV may be worth
considering in the design of mucosal vaccines.
More generally, studies of virus neutralization by antibodies
have traditionally emphasized viral surface antigens. In contrast,
169A. Wright et al. / Virology 356 (2006) 165–170the present and related studies argue that, in certain contexts,
such as mucosal epithelia, antibodies to the internal antigens of
virus particles can play significant roles in host defense.
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